Published in Blood on May 21, 2008
Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol (2010) 4.21
Sensitizing protective tumor microenvironments to antibody-mediated therapy. Cell (2014) 2.43
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood (2010) 2.06
Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood (2011) 1.91
Neutrophils mediate antibody-induced antitumor effects in mice. Blood (2013) 1.66
Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood (2013) 1.55
Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice. J Clin Invest (2011) 1.50
Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica (2009) 1.38
Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function. Leukemia (2012) 1.26
Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. J Clin Invest (2014) 1.21
Evolution of anti-CD20 monoclonal antibody therapeutics in oncology. MAbs (2010) 1.21
Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs (2015) 1.16
Mechanisms of action of CD20 antibodies. Am J Cancer Res (2012) 1.15
Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity. J Immunol (2014) 1.13
Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines. Cell Death Differ (2013) 0.95
Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer. MAbs (2014) 0.91
Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ. J Exp Clin Cancer Res (2014) 0.89
IgA EGFR antibodies mediate tumour killing in vivo. EMBO Mol Med (2013) 0.88
The roles of regulatory B cells in cancer. J Immunol Res (2014) 0.88
The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden. Haematologica (2011) 0.88
Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma. Blood (2015) 0.87
Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial. Haematologica (2014) 0.85
Antibody-dependent cell cytotoxicity in monoclonal antibody-mediated tumor immunotherapy. Oncoimmunology (2012) 0.83
Sensitivity and resistance to EGF-R inhibitors: approaches to enhance the efficacy of EGF-R antibodies. MAbs (2009) 0.83
Immunotherapy for B-cell lymphoma: current status and prospective advances. Front Immunol (2012) 0.82
Galectin-1 drives lymphoma CD20 immunotherapy resistance: validation of a preclinical system to identify resistance mechanisms. Blood (2016) 0.82
Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment. Cancer Immunol Immunother (2011) 0.82
Influence of immunoglobulin isotype on therapeutic antibody function. Blood (2016) 0.78
B Cells with Regulatory Function in Animal Models of Autoimmune and Non-Autoimmune Diseases. Open J Immunol (2015) 0.78
The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia. Leukemia (2016) 0.78
Toll-like Receptor 4 Ligands Down-regulate Fcγ Receptor IIb (FcγRIIb) via MARCH3 Protein-mediated Ubiquitination. J Biol Chem (2015) 0.77
Signaling by Antibodies: Recent Progress. Annu Rev Immunol (2017) 0.76
Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies. Biochim Biophys Acta (2016) 0.76
Macrophages in the liver prevent metastasis by efficiently eliminating circulating tumor cells after monoclonal antibody immunotherapy. Oncoimmunology (2014) 0.75
Tumor-associated macrophages in diffuse large B-cell lymphoma. Haematologica (2015) 0.75
Anti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicity. Oncoimmunology (2016) 0.75
CTLA-4 Limits Anti-CD20-Mediated Tumor Regression. Clin Cancer Res (2016) 0.75
Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy. Oncogene (2016) 0.75
A potent human neutralizing antibody Fc-dependently reduces established HBV infections. Elife (2017) 0.75
B cell regulation in cancer and anti-tumor immunity. Cell Mol Immunol (2017) 0.75
The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature (1986) 14.56
Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods (1994) 13.53
Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med (2000) 13.24
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood (2002) 8.76
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol (2003) 6.77
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood (1994) 6.47
IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol (1997) 4.32
FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity (2005) 4.22
The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells. J Exp Med (1988) 3.80
The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med (2004) 3.56
Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae. Infect Immun (1999) 3.39
The binding site for C1q on IgG. Nature (1988) 3.03
Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol (2005) 3.00
Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood (1984) 2.74
Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol (2003) 2.62
CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood (2001) 2.53
CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today (1994) 2.25
Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors. J Exp Med (1999) 2.23
Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity (2003) 2.20
The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematologica (2006) 2.19
Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood (1998) 2.17
The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J Immunol (2005) 2.16
Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood (2003) 2.04
Mouse CD20 expression and function. Int Immunol (2004) 2.02
CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity. J Immunol (1996) 1.90
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood (2002) 1.87
Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol (2001) 1.86
Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med (2006) 1.80
Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J Cell Biol (1993) 1.80
Rituximab therapy in malignant lymphoma. Oncogene (2007) 1.66
Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans (1997) 1.45
CD22 ligand binding regulates normal and malignant B lymphocyte survival in vivo. J Immunol (2006) 1.37
IgEb immune complexes activate macrophages through FcgammaRIV binding. Nat Immunol (2007) 1.27
Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. Springer Semin Immunopathol (2006) 1.24
Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment. Hematol J (2001) 1.20
An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab. Blood (2002) 1.17
Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J Immunother (2001) 1.15
Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proc Natl Acad Sci U S A (2005) 1.15
In vivo anti-complementary activities of the cobra venom factors from Naja naja and Naja haje. J Immunol Methods (1991) 1.09
Circulation of human hematopoietic cells in severe combined immunodeficient mice after Cl2MDP-liposome-mediated macrophage depletion. Blood (1995) 1.05
Anti-B1 monoclonal antibody and complement treatment in autologous bone-marrow transplantation for relapsed B-cell non-Hodgkin's lymphoma. Lancet (1984) 0.98
HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor. Blood (1996) 0.97
Complement in BuB/BnJ mice revisited: serum C3 levels and complement opsonic activity are not elevated. Mol Immunol (2005) 0.90
A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody. J Immunol Methods (1997) 0.88
The CCL3 family of chemokines and innate immunity cooperate in vivo in the eradication of an established lymphoma xenograft by rituximab. J Immunol (2007) 0.87
Enhanced killing of B lymphoma cells by granulocyte colony-stimulating factor-primed effector cells and Hu1D10--a humanized human leucocyte antigen DR antibody. Br J Haematol (2002) 0.85
A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity (2008) 6.73
Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest (2008) 5.85
B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat Med (2011) 5.16
Innate and adaptive immunity cooperate flexibly to maintain host-microbiota mutualism. Science (2009) 4.45
B-1a and B-1b cells exhibit distinct developmental requirements and have unique functional roles in innate and adaptive immunity to S. pneumoniae. Immunity (2005) 4.31
Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood (2010) 4.28
B lymphocytes: how they develop and function. Blood (2008) 4.07
Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev (2008) 3.67
IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology. Cell (2011) 3.61
The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med (2004) 3.56
Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. Nature (2012) 3.48
B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann N Y Acad Sci (2010) 3.07
B-lymphocyte contributions to human autoimmune disease. Immunol Rev (2008) 2.89
The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J Immunol (2009) 2.87
Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood (2012) 2.86
Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice. Proc Natl Acad Sci U S A (2007) 2.81
B cell depletion reduces the development of atherosclerosis in mice. J Exp Med (2010) 2.79
Degos disease: a C5b-9/interferon-α-mediated endotheliopathy syndrome. Am J Clin Pathol (2011) 2.50
Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J Immunol (2008) 2.45
Regulatory B cells (B10 cells) and regulatory T cells have independent roles in controlling experimental autoimmune encephalomyelitis initiation and late-phase immunopathogenesis. J Immunol (2010) 2.44
De novo intraepidermal epithelioid melanocytic dysplasia as a marker of the atypical mole phenotype -- a clinical and pathological study of 75 patients. J Cutan Pathol (2005) 2.38
Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology (2008) 2.16
Calciphylaxis: emerging concepts in prevention, diagnosis, and treatment. Semin Dial (2002) 2.16
The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J Immunol (2005) 2.16
CD22 regulates B lymphocyte function in vivo through both ligand-dependent and ligand-independent mechanisms. Nat Immunol (2004) 2.16
CD20 deficiency in humans results in impaired T cell-independent antibody responses. J Clin Invest (2009) 2.15
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood (2010) 2.06
B cell depletion delays collagen-induced arthritis in mice: arthritis induction requires synergy between humoral and cell-mediated immunity. J Immunol (2007) 2.05
Mouse CD20 expression and function. Int Immunol (2004) 2.02
Regulatory B cells (B10 cells) have a suppressive role in murine lupus: CD19 and B10 cell deficiency exacerbates systemic autoimmunity. J Immunol (2010) 1.98
B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions. J Immunol (2008) 1.96
Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med (2006) 1.80
B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J Immunol (2010) 1.77
Cutaneous vasculitis: a review. J Cutan Pathol (2003) 1.74
Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med (2004) 1.70
IL-10-producing regulatory B cells (B10 cells) in autoimmune disease. Arthritis Res Ther (2013) 1.66
B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol (2006) 1.64
CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest (2002) 1.61
Protective and pathogenic roles for B cells during systemic autoimmunity in NZB/W F1 mice. J Immunol (2010) 1.61
Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum (2012) 1.56
A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients. Clin Cancer Res (2004) 1.55
Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutants. J Exp Med (2011) 1.53
CD83 expression influences CD4+ T cell development in the thymus. Cell (2002) 1.52
New prospects for autoimmune disease therapy: B cells on deathwatch. Arthritis Rheum (2006) 1.51
Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice. J Clin Invest (2011) 1.50
Susac syndrome: an organ-specific autoimmune endotheliopathy syndrome associated with anti-endothelial cell antibodies. Am J Clin Pathol (2011) 1.50
Complement receptors CD21/35 link innate and protective immunity during Streptococcus pneumoniae infection by regulating IgG3 antibody responses. Immunity (2002) 1.50
Regulatory B cells suppress imiquimod-induced, psoriasis-like skin inflammation. J Leukoc Biol (2013) 1.48
Regulation of B-cell development by BCAP and CD19 through their binding to phosphoinositide 3-kinase. Blood (2007) 1.48
Usefulness of anti-cyclic citrullinated peptide antibody and rheumatoid factor to detect rheumatoid arthritis in patients with systemic sclerosis. Rheumatology (Oxford) (2010) 1.46
B lymphocytes trigger monocyte mobilization and impair heart function after acute myocardial infarction. Nat Med (2013) 1.43
Leukocyte migration is regulated by L-selectin endoproteolytic release. Immunity (2003) 1.42
Regulatory B10 cells differentiate into antibody-secreting cells after transient IL-10 production in vivo. J Immunol (2011) 1.40
Light-chain-restricted plasmacellular infiltrates in necrobiosis lipoidica -- a clue to an underlying monoclonal gammopathy. J Cutan Pathol (2005) 1.39
Identifying regulatory B cells (B10 cells) that produce IL-10 in mice. Methods Mol Biol (2011) 1.39
FDG-PET imaging in primary bilateral adrenal lymphoma: a case report and review of the literature. Clin Nucl Med (2005) 1.38
CD22 ligand binding regulates normal and malignant B lymphocyte survival in vivo. J Immunol (2006) 1.37
CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction. Adv Immunol (2005) 1.36
L-selectin shedding does not regulate constitutive T cell trafficking but controls the migration pathways of antigen-activated T lymphocytes. J Exp Med (2003) 1.32
18F-FDG PET in evaluation of adrenal lesions in patients with lung cancer. J Nucl Med (2004) 1.31
IL-10-producing regulatory B10 cells inhibit intestinal injury in a mouse model. Am J Pathol (2011) 1.29
Inhibitory role of CD19 in the progression of experimental autoimmune encephalomyelitis by regulating cytokine response. Am J Pathol (2006) 1.28
CD molecules 2005: human cell differentiation molecules. Blood (2005) 1.27
IL-6 blockade attenuates the development of murine sclerodermatous chronic graft-versus-host disease. J Invest Dermatol (2012) 1.26
Malignant adnexal neoplasms. Mod Pathol (2006) 1.26
Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. Springer Semin Immunopathol (2006) 1.24
CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am J Pathol (2008) 1.23
B-lymphocyte depletion ameliorates Sjögren's syndrome in Id3 knockout mice. Immunology (2007) 1.22
B10 cell regulation of health and disease. Immunol Rev (2014) 1.21
The tetraspanin CD81 regulates the expression of CD19 during B cell development in a postendoplasmic reticulum compartment. J Immunol (2003) 1.21